Zai Lab, Argenx rise as muscle-weakening disease drug gets approval in China

Hanall Biopharma

30/06/2023 15:12

** U.S.-listed shares of China-based co Zai Lab Ltd
 9688.HK   ZLAB.O  rise 2.9% to $27.22; while U.S.-listed shares
of Netherlands-based biopharma co Argenx SE  ARGX.O  rise 1.1%
to $387.13
    ** Zai Lab and partner Argenx SE  ARGX.BR  announce China's
National Medical Products Administration has approved Vyvgart as
an add-on to standard therapy for the treatment of adult
patients with generalized myasthenia gravis
    ** Generalized myasthenia gravis is a chronic neuromuscular
disease caused by an abnormal immune reaction that weakens the
muscles in different parts of the body
    ** Zai Lab to seek national reimbursement drug list
inclusion for the drug
    ** Earlier in June, the U.S. FDA approved an under-the-skin
version of the drug with the brand name Vyvgart Hytrulo
    ** U.S.-listed ZLAB stock down ~12% YTD, while ARGX stock up
~2.3% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))